Vinorelbine liposomal - Spectrum Pharmaceuticals

Drug Profile

Vinorelbine liposomal - Spectrum Pharmaceuticals

Alternative Names: Alocrest; INX-0125; Liposomal vinorelbine; Sphingosomal vinorelbine; Vinorelbine liposomal; Vinorelbine tartrate injection; Vinorelbine-TCS

Latest Information Update: 17 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Spectrum Pharmaceuticals; Talon Therapeutics
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-Hodgkin's lymphoma; Solid tumours

Highest Development Phases

  • Suspended Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Breast cancer; Lung cancer

Most Recent Events

  • 17 May 2016 No recent reports on development identified- Phase-I for Breast cancer & Lung cancer in Canada (IV)
  • 30 Sep 2013 Biomarkers information updated
  • 18 Jul 2013 Spectrum Pharmaceuticals acquires Talon Therapeutics' previous rights to liposomal vinorelbine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top